Literature DB >> 11040045

Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.

B R O'Keefe1, S R Shenoy, D Xie, W Zhang, J M Muschik, M J Currens, I Chaiken, M R Boyd.   

Abstract

The novel virucidal protein cyanovirin-N (CV-N) binds with equally high affinity to soluble forms of either H9 cell-produced or recombinant glycosylated HIV-1 gp120 (sgp120) or gp160 (sgp160). Fluorescence polarization studies showed that CV-N is also capable of binding to the glycosylated ectodomain of the HIV-envelope protein gp41 (sgp41) (as well as SIV glycoprotein 32), albeit with considerably lower affinity than the sgp120/CV-N interaction. Pretreatment of CV-N with either sgp120 or sgp41 abrogated the neutralizing activity of CV-N against intact, infectious HIV-1 virions. Isothermal calorimetry and optical biosensor binding studies showed that CV-N bound to recombinant sgp120 with a K(d) value ranging from 2 to 45 nM and to sgp41 with a K(d) value of 606 nM; furthermore, they indicated an approximate 5:1 stoichiometry for CV-N binding to sgp120 and a 1:1 stoichiometry for CV-N binding to sgp41. Circular dichroism studies additionally illuminated the binding of CV-N with both sgp120 and sgp41, providing the first direct evidence that conformational changes are a consequence of CV-N interactions with both HIV-1 envelope glycoproteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040045     DOI: 10.1124/mol.58.5.982

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

1.  Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory.

Authors:  Anthony R Geonnotti; David F Katz
Journal:  Biophys J       Date:  2006-06-30       Impact factor: 4.033

2.  High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.

Authors:  Qinxue Hu; Naheed Mahmood; Robin J Shattock
Journal:  Virology       Date:  2007-07-23       Impact factor: 3.616

3.  Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers.

Authors:  Luca Vangelista; Massimiliano Secchi; Xiaowen Liu; Angela Bachi; Letong Jia; Qiang Xu; Paolo Lusso
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

4.  A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion.

Authors:  Vaibhav Tiwari; Shripaad Y Shukla; Deepak Shukla
Journal:  Antiviral Res       Date:  2009-08-07       Impact factor: 5.970

5.  Multivalent glyconanoparticles with enhanced affinity to the anti-viral lectin Cyanovirin-N.

Authors:  Xin Wang; Elena Matei; Lingquan Deng; Olof Ramström; Angela M Gronenborn; Mingdi Yan
Journal:  Chem Commun (Camb)       Date:  2011-06-30       Impact factor: 6.222

6.  Human Immunodeficiency Virus (HIV) Separation and Enrichment via the Combination of Antiviral Lectin Recognition and a Thermoresponsive Reagent System.

Authors:  Joseph C Phan; Barrett J Nehilla; Selvi Srinivasan; Robert W Coombs; Kim A Woodrow; James J Lai
Journal:  Pharm Res       Date:  2016-07-11       Impact factor: 4.200

7.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

8.  Sensing lectin-glycan interactions using lectin super-microarrays and glycans labeled with dye-doped silica nanoparticles.

Authors:  Xin Wang; Elena Matei; Lingquan Deng; Leonardus Koharudin; Angela M Gronenborn; Olof Ramström; Mingdi Yan
Journal:  Biosens Bioelectron       Date:  2013-03-21       Impact factor: 10.618

Review 9.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

10.  Solution and crystal structures of a sugar binding site mutant of cyanovirin-N: no evidence of domain swapping.

Authors:  Elena Matei; William Furey; Angela M Gronenborn
Journal:  Structure       Date:  2008-08-06       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.